Oncology remains a powerhouse of innovation, with over 100 new cancer treatments expected to launch in the next five years. This rapid pace of development positions oncology as a key growth driver in the biopharmaceutical industry. 

Our latest white paper explores novel modalities like ADCs, bi-/multi-specific antibodies, and radioligand therapies, and provides insights into the competitive dynamics and success factors for oncology innovators.